⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL28143520 | 0.91 | — | — | |
| SCHEMBL180757 | 0.89 | — | — | |
| SCHEMBL14151417 | 0.80 | — | — | |
| SCHEMBL11659799 | 0.80 | — | — | |
| SCHEMBL15788977 | 0.80 | — | — | |
| SCHEMBL5897645 | 0.80 | — | — | |
| SCHEMBL15366348 | 0.80 | — | — | |
| SCHEMBL4301414 | 0.80 | — | — | |
| SCHEMBL7056855 | 0.80 | — | — | |
| SCHEMBL7615128 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4673451-A1 | POLYMERIZABLE MONOMER | Universität Linz (AT) | 2026-01-07 | — | — | EP | disclosed |
| US-12478616-B2 | PI3K inhibitors and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2025-11-25 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-115989224-B | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119255997-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119233976-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024178449-A1 | POLYMERIZABLE MONOMER | Universität Linz (AT) | 2024-09-06 | — | — | WO | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| US-4886790-A | CHEMOTPHERAPY | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0251724-A2 | Compositions containing bisphenol compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-01-07 | — | — | EP | disclosed |
| EP-0227528-A1 | Process for preparing halogenated trialkyl phosphate esters | THE DOW CHEMICAL COMPANY (US) | 1987-07-01 | — | — | EP | disclosed |
| US-4544501-A | ANTINEOPLASTIC | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1985-10-01 | — | — | US | disclosed |
| US-4177200-A | Silyl phosphates as neutralizing agents for alkali metal hydroxides | GENERAL ELECTRIC COMPANY (US) | 1979-12-04 | — | — | US | disclosed |
| US-4125551-A | FROM A POLYSILOXANE AND PHOSPHORIC ACID | GENERAL ELECTRIC COMPANY (US) | 1978-11-14 | — | — | US | disclosed |